In 2006 was created BioGeneration Ventures, which is appeared as VC. The main office of represented VC is situated in the Naarden. The company was established in Europe in The Netherlands.
The top amount of exits for fund were in 2015. Deals in the range of 10 - 50 millions dollars are the general things for fund. Comparing to the other companies, this BioGeneration Ventures performs on 10 percentage points less the average number of lead investments. Considering the real fund results, this VC is 23 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2017. Despite it in 2019 the fund had an activity. The fund is generally included in less than 2 deals every year.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the BioGeneration Ventures, startups are often financed by Thuja Capital, NV NOM, MedSciences Capital. The meaningful sponsors for the fund in investment in the same round are Forbion Capital Partners, New Science Ventures, BOM Capital. In the next rounds fund is usually obtained by Omnes Capital, Forbion Capital Partners, Erasmus MC Biomedical Fund.
Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight AcertaPharma, Mellon Medical, Scenic Biotech. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 3 or 5+ of the founder, the chance for it to be financed is low. Among the most successful fund investment fields, there are Therapeutics, Health Care. For fund there is a match between the location of its establishment and the land of its numerous investments - The Netherlands.
Besides them, we counted 5 critical employees of this fund in our database.
Funds with similar focus
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Tanai Therapeutics | 19 Sep 2024 | Gent, Oost-Vlaanderen, Belgium | |||
Brenig Therapeutics | $65M | 24 Jul 2024 | Dover, Delaware, United States | ||
VectorY | $152M | 13 Nov 2023 | - | ||
Tessellate BIO | $9M | 17 Oct 2023 | Naarden, Noord-Holland, The Netherlands | ||
Mironid | $42M | 13 Sep 2023 | United Kingdom, Scotland, United Kingdom | ||
VarmX | $41M | 25 May 2023 | Leiden, South Holland, Netherlands | ||
Dualyx | $47M | 15 May 2023 | Ghent, Oost-Vlaanderen, Belgium | ||
Complement Therapeutics | $84M | 17 Apr 2023 | London, England, United Kingdom | ||
Panome Bio | $6M | 24 Feb 2023 | St Louis, Missouri, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Tanai Therapeutics | 19 Sep 2024 | Gent, Oost-Vlaanderen, Belgium | |||
Brenig Therapeutics | $65M | 24 Jul 2024 | Dover, Delaware, United States | ||
VectorY | $152M | 13 Nov 2023 | - | ||
Tessellate BIO | $9M | 17 Oct 2023 | Naarden, Noord-Holland, The Netherlands | ||
Mironid | $42M | 13 Sep 2023 | United Kingdom, Scotland, United Kingdom | ||
VarmX | $41M | 25 May 2023 | Leiden, South Holland, Netherlands | ||
Dualyx | $47M | 15 May 2023 | Ghent, Oost-Vlaanderen, Belgium | ||
Complement Therapeutics | $84M | 17 Apr 2023 | London, England, United Kingdom | ||
Panome Bio | $6M | 24 Feb 2023 | St Louis, Missouri, United States |